|Articles|August 1, 2011

Applied Clinical Trials

  • Applied Clinical Trials-08-01-2011
  • Volume 20
  • Issue 8

Latin America Research Stats

Starting with Eastern European sites in the 1990s, companies have increasingly selected investigator sites outside of North America and Western Europe.

Starting with Eastern European sites in the 1990s, companies have increasingly selected investigator sites outside of North America and Western Europe. Recently, drug development organizations have also been recruiting sites and enrolling patients in more remote locations such as Asia, India, and Latin America. Little research has been done on the attitudes of investigators in these newer geographies: why they participate in clinical trial research, what they like and dislike about their clinical trial experiences, and their thoughts about organizations conducting these clinical studies. TTC and the University of the Sciences in Philadelphia conducted a 4,000 multinational site survey.

The overall response distribution in Latin America closely followed the distribution of sites by country and therapeutic areas recorded in ClinicalTrials.gov. The complete questionnaire and respondent answers can be found online.

Latin America and US investigators emphasize the importance of medical innovation as grounds for their involvement in clinical studies. For Latin American physicians, this interest in innovation holds whether the research directly touches their patients or not. Latin American investigators are especially keen to share their clinical trial derived knowledge with other physicians.

—TTC and the University of Sciences in Philadelphia (for more information, contact help@ttc-llc.com).

Articles in this issue


Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.